Vaccine Safety and DMT for Highly Active MS: New Data : vima

Many clinicians delay CD20 treatment until vaccine schedules are complete. A study suggests that this precaution may not be necessary.

Related Keywords

Spain , Emory University , Georgia , United States , Atlanta , Barcelona , Comunidad Autonoma De Cataluna , Hebron , Israel General , Israel , Universitari Vall , John Cunningham , Sclerosis Centre Of Catalonia Cemcat , Department Of Neurology , Division Of Pediatric Neurology , Multiple Sclerosis Centre , Hospital Universitari Vall , Universitat Aut , Medscape Medical , Barcelona Treatment , Expanded Disability Status Scale , Medscape Medical News , Grace Gombolay , Pediatric Neurology , Pediatric Neuroimmunology , Multiple Sclerosis Clinic , Multiple Sclerosis Ms , S Multiple Sclerosis , Immunizations , Vaccination , Covid 19 Vaccine , Coronavirus Vaccine , Vaccine , Vaccines , Hepatitisb Hbv Virus , Gbv , Children , Child , Childhood , Ediatrics , Kids , Covid 19 , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e ,